Addex Therapeutics Ltd (ADXN)

CIK 0001574232 · Healthcare · Biotechnology

Recent Filing Index

Form Filed Qtr End F_Period 8K: Earnings Release
Latest FY-2025 —
FY-2024 —
FY-2023 —

Filing Summary

Report Name | Notes Fiscal Period (Annual) Fiscal Period (Quarter)
Document and Entity Information
—
Statements
Consolidated Balance Sheets
—
Consolidated Statements of Comprehensive Loss
—
Consolidated Statements of Profit Or Loss
—
Consolidated Statements of Comprehensive Profit Or Loss
—
Consolidated Statements of Changes In Equity
—
Consolidated Statements of Cash Flows
—
Consolidated Statements of Cash Flows (P)
—
Notes
Cash and Cash Equivalents
—
Commitments and Contingencies
—
Cybersecurity Risk Management and Strategy Disclosure
—
Deferred Income
—
Derivative Financial Instruments
—
Discontinued Operations
—
Equipment
—
Events After The Balance Sheet Date
—
Finance Result, Net
—
Financial Assets At Fair Value Through Other Comprehensive Income
—
Financial Risk Management
—
General Information
—
Insider Trading Policies and Procedures
—
Intangible Assets
—
Interests In Associates
—
Loss Per Share
—
Material Accounting Estimates and Judgments
—
Non-current Financial Assets
—
Operating Costs
—
Other Current Assets
—
Other Income
—
Payables and Accruals
—
Profit Or Loss Per Share
—
Property, Plant and Equipment
—
Related Party Transactions
—
Retirement Benefits Obligations
—
Revenue From Contract With Customer
—
Right-of-use Assets
—
Segment Information
—
Share Capital
—
Share-based Compensation
—
Staff Costs
—
Summary of Material Accounting Policies
—
Taxes
—